Breathing Easier: Understanding and Managing Pulmonary Hypertension in Asia
"Despite modern advancements, pulmonary hypertension remains a critical health challenge. Learn about the latest research and treatment options available in Asia to improve outcomes and enhance quality of life."
Pulmonary arterial hypertension (PAH) has significantly risen in prominence over the past two decades. This surge in attention is largely fueled by the development of innovative treatments and deeper insights into the genetic and pathological underpinnings of the disease. Once considered a rare and often overlooked condition, PAH now commands major sessions at international conferences, driving increased frequency of discussions at both national and global levels. This heightened focus has spurred the formation of new national societies dedicated to advancing research and treatment.
Alongside this growing interest, numerous national and international registries have emerged, aiming to evaluate patient outcomes in real-world settings. These include the REVEAL registry in the USA, the PHSANZ registry in Australia and New Zealand, and several European registries. These registries are vital in tracking and understanding the effectiveness of current treatments and identifying areas for improvement in patient care.
The recent publication in 'Respirology' by Lim et al. marks an important contribution to understanding the epidemiology and outcomes of PAH. As the first report from a registry in the Asia-Pacific region (Singapore), it offers over a decade of follow-up data (2003-2016). This study enriches our understanding of how PAH is managed and the challenges faced in this specific geographic context.
Survival Statistics Highlight the Stakes of Treatment
According to ZipDo's 2026 education report, the 5-year survival rate for PAH patients on modern therapy (including PVAs and oxygen) is approximately 60–70%, compared with under 20% without treatment. A separate source cites a median survival of 2.8 years after diagnosis for idiopathic pulmonary arterial hypertension without targeted therapy, based on historical cohort data. Both figures underscore how dramatically outcomes depend on access to treatment. Data aggregators such as Gitnux note that PH statistics are drawn from peer-reviewed journals, government agencies, and professional bodies, with each figure independently verified and cross-referenced against independent databases.
From Catheter to Echo: Diagnosis and Its Bottlenecks
Pulmonary hypertension is defined as a mean pulmonary artery pressure of ≥25 mmHg as confirmed on right heart catheterisation, the reference standard for diagnosis. Because catheterisation is invasive, clinicians increasingly rely on noninvasive estimation of pulmonary vascular resistance via echocardiography, and a UK working party has recommended a standardised approach for echocardiographic right ventricular and pulmonary haemodynamic measurements at rest. Given the many causes of PH, diagnosing pulmonary arterial hypertension requires a systematic approach to the breathless patient and screening of high-risk groups. Palliative care involvement remains limited and often delayed, and adoption of a standardized referral approach based on clinical or patient triggers could facilitate earlier involvement as an adjunct to ongoing disease-directed care.
From an 1891 Mystery to a Formal Definition
Doctors first described pulmonary hypertension in 1891, though its cause remained a mystery for decades. Historical accounts trace the study of the condition back to the discovery of the pulmonary circulation and recognition of elevated pulmonary artery pressure as its key hemodynamic characteristic. The previously used term "primary pulmonary hypertension" was later replaced by the terms idiopathic and hereditary PAH. It was also confirmed that right heart catheterisation is required to diagnose PH, formally defined by a mean pulmonary artery pressure of >25 mmHg at rest or >30 mmHg with exercise.
Key Insights from the Singapore PAH Registry
The study by Lim et al. provides valuable insights into the long-term management of PAH in Singapore. While the study involves a smaller number of participants compared to other registries, its extended follow-up period offers a unique perspective on disease progression and treatment outcomes. At three years, the survival rate was 70.9%, showing the persistent challenges in managing PAH despite available treatments. This figure aligns with findings from the larger REVEAL registry, highlighting the global complexities of treating this condition.
- Survival rates at 3 years are around 70.9%, indicating ongoing management challenges.
- REVEAL risk score is useful but simplified due to smaller numbers.
- Outcomes vary across registries due to differences in sample sourcing and local practices.
- Extended follow-up provides unique insights into long-term disease management.
New Insights and Renewed Safety Scrutiny
Recent research continues to characterize pulmonary arterial hypertension as a rare but life-threatening disease that progressively narrows the blood vessels of the lungs. Frontiers in Medicine reports that pulmonary hypertension due to left heart disease (PH-LHD) is the most common type of PH, although an accurate prevalence is challenging to establish. In a separate line of investigation, an analysis of the FDA adverse event reporting system (FAERS) database examined the characteristics and timeline of cases of echocardiographic pulmonary hypertension in patients exposed to Fintepla (fenfluramine hydrochloride). This work extends a long-standing literature linking fenfluramine compounds with PH and illustrates how pharmacovigilance data continue to shape understanding of drug-associated disease.
An Incurable Disease With Diagnostic Pitfalls
Despite advances in diagnosis and care, pulmonary hypertension remains a complex, chronic, and currently incurable lung disease, with symptoms including breathlessness, fatigue, dizziness, chest pain, fainting, a bluish color of the lips or skin, and swelling of the arms and legs. The diagnostic pathway is complicated by conditions that mimic or coexist with PH; critical care commentary notes that differentiating abdominal hypertension from abdominal compartment syndrome is generally tricky, with compartment syndrome diagnosed on the basis of higher pressures (at least 20 mmHg) and new organ failure. Such overlapping presentations underscore why clinicians must approach the breathless patient systematically rather than relying on any single finding.
Comparing Classifications and Diagnostic Pathways
Pulmonary hypertension is characterized by elevated pulmonary arterial pressure caused by a broad spectrum of congenital and acquired disease processes, which are currently divided into five groups based on the 2013 WHO classification. Pulmonary arterial hypertension itself is defined as a mean pulmonary arterial pressure greater than 25 mmHg at rest or 30 mmHg during physical activity, and is classified into subgroups including idiopathic and heritable forms. Within these groups, diagnostic comparison matters: in chronic thromboembolic pulmonary hypertension, studies have compared ventilation/perfusion scanning and multidetector CT pulmonary angiography against pulmonary angiography as the reference. PAH is characterized by a progressive increase in pulmonary vascular resistance that leads to altered gas exchange, right heart failure, and ultimately death.
Addressing the Challenges and Future Directions
Despite advancements, the high cost of available drugs and funding limitations in national health systems remain significant barriers. In Singapore, for example, no PAH-specific agents are funded through the national system, creating a substantial negative impact on patients. This lack of funding is a major problem in many Asian-Pacific countries. Even in more fortunate regions, such as Australia, only monotherapy is typically supported by federal health systems, making combination therapies contingent on pharmaceutical industry programs or local health network support. Moving forward, ongoing research is essential to improve PAH therapy. While many efforts are focused on identifying new treatment pathways, it’s crucial to ensure that existing, proven drugs are more readily available and optimally used. The paper by Lim et al. underscores that there is still progress to be made in this area, particularly in ensuring equitable access to care and effective treatment strategies.
What Experts Agree On: A Distinct, Severe Disease
Pulmonary hypertension is a condition of increased blood pressure in the arteries of the lungs, with symptoms including shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat. Compared with systemic hypertension, PH only causes an increase in the arteries in the lungs rather than in arteries throughout the body. Expert commentary nonetheless describes PH as a severe condition with a poor prognosis despite recent treatment advances. All currently available therapeutic agents mainly restore dysfunction of the pulmonary vascular tone, underscoring that treatment targets vascular regulation rather than structural reversal.
Reversal, Pipeline Growth, and Personalization
Remarkable advances in the pharmacological management of pulmonary hypertension have been achieved in the past 20 years, but the search continues for treatments to reverse the relentless vascular remodelling that characterises the disease. The development pipeline remains active: DelveInsight's pipeline insight report profiles more than 45 companies and 50+ pipeline drugs across the PH landscape, spanning clinical and nonclinical stage products. A further frontier is personalization, with observations that the presentation of PAH has varied in patients of different ethnic and racial groups, raising the possibility that future treatment may depend on race and ethnicity.
Access, Diagnosis, and the Weight of Delay
A key systemic challenge is that pulmonary hypertension requires invasive hemodynamic confirmation via right heart catheterisation, which is not always accessible; noninvasive imaging is central to triage, and researchers are evaluating the comparative diagnostic performance of conventional methods versus artificial intelligence (AI) approaches. In practice, the right treatment approach depends on an accurate diagnosis, disease severity, and the patient's overall health, with planning focused on improving symptoms, supporting heart function, and reducing disease burden. Patient advocacy groups further highlight diagnosis challenges, the emotional impact of the illness, and the value of community support alongside treatment progress.
Registries Reveal the Real Burden
Pulmonary arterial hypertension is a rare, progressive disorder that eventually leads to death if left untreated, which is why insights into current real-world management and characterisation of patients are urgently needed. Real-world registries capture the human burden of the disease: data from the Hellenic pulmonary hypertension registry (HOPE) and a Portuguese expert referral centre describe PH as a heterogeneous, debilitating condition with a highly relevant impact on functional capacity, quality of life, and life-expectancy. Interim analyses from ongoing real-world studies continue to clarify how patients are actually managed and what outcomes they achieve outside the controlled setting of clinical trials.